Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):9208-9215. doi: 10.26355/eurrev_202009_22873.
In December 2019, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection broke out in Wuhan, China. However, we still lack a comprehensive understanding of this emerging virus. In this manuscript, we collected relevant articles and reviewed the characteristics about SARS-CoV-2.
We performed an online search on PubMed and Web of Science with the keywords COVID-19, 2019-nCoV and SARS-CoV-2, and summarized the epidemiology, virology, clinical features and treatments of SARS-CoV-2 infection.
We retrieved 157 published papers about SARS-CoV-2 from January, 2020 to April, 2020. We found that SARS-CoV-2 was a kind of virus with low mortality rate and high infectivity. This virus can enter human cells through angiotensin-converting enzyme 2 (ACE2) in alveoli and activate immune response in human body. SARS-CoV-2 infection can be classified as asymptomatic, mild, common, severe, and critical. We summarized antiviral drugs against SARS-CoV-2, such as remdesivir, hydroxychloroquine and favipiravir. Because the vaccine of SARS-CoV-2 is developing, more clinical studies are needed to verify the safety and efficacy of these treatments.
SARS-CoV-2 is a novel coronavirus that has caused a global pandemic. We should pay more attention to prevent SARS-CoV-2 and try to control it sooner.
2019 年 12 月，严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）在中国武汉爆发。然而，我们对这种新兴病毒仍然缺乏全面的了解。在本手稿中，我们收集了相关文章，综述了 SARS-CoV-2 的特征。
我们在 PubMed 和 Web of Science 上使用 COVID-19、2019-nCoV 和 SARS-CoV-2 等关键词进行了在线搜索，并总结了 SARS-CoV-2 感染的流行病学、病毒学、临床特征和治疗方法。
我们从 2020 年 1 月至 4 月检索到了 157 篇关于 SARS-CoV-2 的已发表论文。我们发现，SARS-CoV-2 是一种死亡率低但传染性高的病毒。这种病毒可以通过肺泡中的血管紧张素转换酶 2（ACE2）进入人体细胞，并激活人体的免疫反应。SARS-CoV-2 感染可分为无症状、轻症、普通、重症和危重症。我们总结了针对 SARS-CoV-2 的抗病毒药物，如瑞德西韦、羟氯喹和法匹拉韦。由于 SARS-CoV-2 的疫苗正在研发中，需要更多的临床研究来验证这些治疗方法的安全性和有效性。
SARS-CoV-2 是一种引起全球大流行的新型冠状病毒。我们应该更加关注预防 SARS-CoV-2 并尽早尝试控制它。
